ArticleCancer science2009
Deficiency of antiproliferative family protein Ana correlates with development of lung adenocarcinoma.
Article in Cancer science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- RNA binding protein PUM2 promotes hepatocellular carcinoma proliferation and apoptosis via binding to the 3'UTR of BTG3.Oncology letters · 2022Article
- The clinicopathological significances and related signal pathways of BTG3 mRNA expression in cancers: A bioinformatics analysis.Frontiers in genetics · 2022Article
- Loss of the tumor suppressor BTG3 drives a pro-angiogenic tumor microenvironment through HIF-1 activation.Cell death & disease · 2020Article
- Article
- Catalytides derived from the Box A region in the ANA/BTG3 protein cleave amyloid-β fragment peptide.Heliyon · 2019Article
- Suppression of miR-93-5p inhibits high-risk HPV-positive cervical cancer progression via targeting of BTG3.Human cell · 2019Article
- Restraining the Proliferation of Acute Lymphoblastic Leukemia Cells by Genistein through Up-regulation of B-cell Translocation Gene-3 at Transcription Level.Galen medical journal · 2019Article
- Direct Downregulation of B-Cell Translocation Gene 3 by microRNA-93 Is Required for Desensitizing Esophageal Cancer to Radiotherapy.Digestive diseases and sciences · 2017Article
- The interplay between transcription and mRNA degradation inMicrobial cell (Graz, Austria) · 2017Review
- The suppressing effects of BTG3 expression on aggressive behaviors and phenotypes of colorectal cancer: An in vitro and vivo study.Oncotarget · 2017Article
- Expression and prognosis analyses of the Tob/BTG antiproliferative (APRO) protein family in human cancers.PloS one · 2017Article
- The BTG4 and CAF1 complex prevents the spontaneous activation of eggs by deadenylating maternal mRNAs.Open biology · 2016Article
- Genomic Analyses of Sperm Fate Regulator Targets Reveal a Common Set of Oogenic mRNAs in Caenorhabditis elegans.Genetics · 2016Article
- MiR-4295 promotes cell growth in bladder cancer by targeting BTG1.American journal of translational research · 2016Article
- The roles of BTG3 expression in gastric cancer: a potential marker for carcinogenesis and a target molecule for gene therapy.Oncotarget · 2015Article
- BTG1 potentiates apoptosis and suppresses proliferation in renal cell carcinoma by interacting with PRMT1.Oncology letters · 2015Article
- BTG3 upregulation induces cell apoptosis and suppresses invasion in esophageal adenocarcinoma.Molecular and cellular biochemistry · 2015Article
- Down-regulation of BTG3 promotes cell proliferation, migration and invasion and predicts survival in gastric cancer.Journal of cancer research and clinical oncology · 2015Article
- Candidate tumor suppressor B-cell translocation gene 3 impedes neoplastic progression by suppression of AKT.Cell death & disease · 2015Article
- Decreased expression of BTG3 was linked to carcinogenesis, aggressiveness, and prognosis of ovarian carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The abundant in neuroepithelium area (ana) gene was originally identified as a member of the tob/btg family of antiproliferative genes. Like the other family members, Ana inhibits growth of NIH3T3 cells when overexpressed. However, whether or not Ana is involved in tumor progression has been elusive. Here, we show that expression of ana is relatively high in the lung, the expression being restricted in type II alveolar epithelial cells. We further show that ana expression is reduced in 97% of the human lung cancer cell lines examined (61/63) and 86% of clinical samples from lung adenocarcinoma patients (36/42). Long-term observation of ana-deficient (ana−/–) mice reveals that 8% of them develop lung tumors (5/66) by 21 months after birth, while 0% of wild-type mice (0/35) develop the same type of tumors. We also show that exogenously expressed ana gene product suppresses the levels of matrix metalloproteinase-2 (MMP-2) and plasminogen activator inhibitor-1 (PAI-1) expression in lung cancer cells. Taken together, we propose that ana functions as a tumor suppressor and that its product inhibits tumor progression as well by suppressing angiogenesis, invasion, and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.